A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Kathleen N. Moore(University of Oklahoma Medical Center), Roy L. Maute(Io Therapeutics (United States)), Yan V. Wang(Menlo School), David S. Miller(Southwestern Medical Center), Balaji Agoram(Menlo School), Chris H. Takimoto(Menlo School), Gini F. Fleming(University of Chicago Medical Center), John W. Moroney(University of Chicago), John B. Liao(Seattle Pacific University), Amita Patnaik(South Texas Accelerated Research Therapeutics), Matt Axt(Menlo School), Isagani Chico, Mark P. Chao(Stanford Medicine), Andreas Schröeder(Merck KGaA, Darmstadt (Germany)), Jens-Peter Volkmer(Menlo School)
Cited by 37
Related Papers
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*
|Journal of Clinical Oncology|2001|819
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies
|International Journal of Radiation Oncology*Biology*Physics|2002|468